Mylan Lab (NYSE: MYL), a leading pharmaceutical company, closed at $13.53. Goldman Sachs says, "Upgrading to Buy with $19 price target, we see a bottom in shares." MYL overall option implied volatility of 46 is above its 26-week average of 39 according to Track Data, suggesting larger price movement.
Forest Labs (NYSE: FRX), a U.S.-based pharmaceutical company, closed at $36.71. Cowen says "current pipeline is more valuable than generally perceived, and we believe FRX shares can outperform the market by 15-20% as pipeline viability improves." FRX overall option implied volatility of 44 is above its 26-week average of 37 according to Track Data, suggesting larger price movement.
Daily Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com
Cramer on BloggingStocks: The Fed's push for TARP payback 
Hewlett-Packard reports growth in profit and operating margin in Q4
Before the bell: Stocks futures steady ahead of GDP, housing data
